Nandrolone decanoate for the treatment of erythropoietin refractory anemia: a case series.

Abstract

Erythropoietin refractory anemias represent a continuing and increasing burden on the healthcare system. The current practice of providing these patients with rHuEPO does not seem to be working. Fewer than 50% of patients respond in some studies. We demonstrate that androgens have multiple benefits in this population. They control anemia and stop transfusion dependence and improve nutritional parameters. In some patients, they also have a salutary effect on both white blood cell and platelet counts.

• Authors: Bobby Chawla, Fahad M Iqbal, Manjeet S Chawla
• Journal: Comprehensive therapy (Compr Ther) 2009 Fall-Winter Vol. 35 Issue 3-4 Pg. 199-203 ISSN: 0098-8243 [Print] United States
• PMID: 20043618 (Publication Type: Case Reports, Journal Article)

Chemical References

• Androgens
• Hematinics
• Hemoglobins
• Recombinant Proteins
• Erythropoietin
• Nandrolone
• Nandrolone Decanoate

Topics

• Aged
• Androgens (administration & dosage, therapeutic use)
• Anemia (drug therapy, etiology)
• Blood Cell Count
• Blood Transfusion
• Drug Resistance
• Erythropoietin (therapeutic use)
• Female
• Hematinics (therapeutic use)
• Hemoglobins (analysis)
• Humans
• Middle Aged
• Nandrolone (administration & dosage, analogs & derivatives, therapeutic use)
• Nandrolone Decanoate
• Neoplasms (complications)
• Recombinant Proteins
• Recurrence